Tesamorelin 10mg — Stabilized GHRH analog research peptide (CAS 218949-48-5). FDA-referenced (Egrifta). 99% purity, USA domestic. Same-day shipping. Free shipping over $200.
$59.00
101 in stock
Tesamorelin 10mg is a research-grade stabilized synthetic analog of growth hormone-releasing hormone (GHRH) (CAS 218949-48-5), distinguished by the addition of a trans-3-hexenoic acid group at the N-terminus to enhance stability. Tesamorelin is one of the most clinically-referenced synthetic GHRH analogs in existence, having received FDA approval under the trade name Egrifta® for HIV-associated lipodystrophy — making it one of the few research peptides with a validated human clinical data set. It is studied for GH/IGF-1 axis activation, visceral adipose tissue reduction, and GHRH receptor pharmacology.
Tesamorelin 10mg (CAS 218949-48-5) is used in professional pre-clinical research for:
When searching for tesamorelin 10mg for sale or a trusted source to buy tesamorelin research peptide online, researchers choose Combat Research for quality and reliable US fulfillment:
| Property | Value |
|---|---|
| CAS Number | 218949-48-5 |
| Brand Name | Egrifta® (FDA-approved for HIV-associated lipodystrophy) |
| Also Known As | TH9507, GHRH analog, trans-3-hexenoic acid GHRH |
| Peptide Class | Stabilized GHRH analog (44 amino acids) |
| Form | Lyophilized Powder |
| Vial Size | 10mg |
| Purity | ≥99% |
| Storage | Refrigerated, protected from light and moisture |
Tesamorelin 10mg is supplied as a lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water or sterile saline under aseptic conditions. Store reconstituted solution refrigerated at 2–8°C. Minimize freeze-thaw cycles to preserve peptide integrity.
Tesamorelin (CAS 218949-48-5) is sold exclusively for pre-clinical and in vitro laboratory research. Not for human or animal consumption outside of FDA-approved clinical indications. All research use must comply with applicable local, state, and federal regulations governing research compounds.
Tesamorelin (CAS 218949-48-5) is a stabilized synthetic GHRH analog with a trans-3-hexenoic acid N-terminal modification that enhances plasma stability. It is FDA-approved as Egrifta for HIV-associated lipodystrophy and is studied in research for GH/IGF-1 axis activation, visceral fat metabolism, and GHRH receptor pharmacology.
Yes. Tesamorelin is FDA-approved under the brand name Egrifta for treatment of HIV-associated lipodystrophy, making it one of the few synthetic GHRH analogs with a validated human clinical dataset. In research settings, it is studied for GH/IGF-1 axis modulation, metabolic research, and comparative GHRH pharmacology.
CAS 218949-48-5. Also known as TH9507. FDA-approved brand name: Egrifta. 44-amino-acid stabilized GHRH analog. PubChem CID: 6918296.
Tesamorelin is a 44-amino-acid GHRH analog stabilized with a trans-3-hexenoic acid group, with a plasma half-life of approximately 25-30 minutes. CJC-1295 DAC uses albumin-binding technology to extend half-life to 6-8 days. Tesamorelin produces more physiological GH pulsatility vs. the sustained GH elevation of CJC-1295 DAC.
Tesamorelin is studied for GHRH receptor agonism, GH/IGF-1 axis signaling, visceral adipose tissue metabolism and lipodystrophy models, metabolic syndrome and insulin sensitivity research, GH-mediated cognitive function, and comparative GHRH analog pharmacology.
Reconstitute with bacteriostatic water or sterile saline under aseptic conditions. Gently swirl until fully dissolved. Store refrigerated at 2-8 degrees Celsius. Minimize freeze-thaw cycles to preserve peptide integrity.
Tesamorelin 10mg is available from Combat Research with 99% purity, USA domestic stock, same-day shipping, and free shipping on orders over .
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.